JP2003521914A5 - - Google Patents

Download PDF

Info

Publication number
JP2003521914A5
JP2003521914A5 JP2001557910A JP2001557910A JP2003521914A5 JP 2003521914 A5 JP2003521914 A5 JP 2003521914A5 JP 2001557910 A JP2001557910 A JP 2001557910A JP 2001557910 A JP2001557910 A JP 2001557910A JP 2003521914 A5 JP2003521914 A5 JP 2003521914A5
Authority
JP
Japan
Prior art keywords
inhibitor
human
mammal
exchange column
human mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001557910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003521914A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2001/000068 external-priority patent/WO2001057079A2/en
Publication of JP2003521914A publication Critical patent/JP2003521914A/ja
Publication of JP2003521914A5 publication Critical patent/JP2003521914A5/ja
Withdrawn legal-status Critical Current

Links

JP2001557910A 2000-01-31 2001-01-31 トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター Withdrawn JP2003521914A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US17931000P 2000-01-31 2000-01-31
EP00200320.0 2000-01-31
US60/179,310 2000-01-31
EP00200320 2000-01-31
US18758000P 2000-03-07 2000-03-07
US60/187,580 2000-03-07
EP00200810.0 2000-03-07
EP00200810 2000-03-07
PCT/NL2001/000068 WO2001057079A2 (en) 2000-01-31 2001-01-31 C1 inhibitor produced in the milk of transgenic mammals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011270236A Division JP2012050465A (ja) 2000-01-31 2011-12-09 トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター

Publications (2)

Publication Number Publication Date
JP2003521914A JP2003521914A (ja) 2003-07-22
JP2003521914A5 true JP2003521914A5 (cg-RX-API-DMAC7.html) 2008-02-28

Family

ID=56290105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001557910A Withdrawn JP2003521914A (ja) 2000-01-31 2001-01-31 トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター

Country Status (9)

Country Link
EP (1) EP1252184B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003521914A (cg-RX-API-DMAC7.html)
AT (1) ATE382635T1 (cg-RX-API-DMAC7.html)
CA (1) CA2398707C (cg-RX-API-DMAC7.html)
DE (2) DE60132169T2 (cg-RX-API-DMAC7.html)
DK (1) DK1252184T3 (cg-RX-API-DMAC7.html)
ES (1) ES2299473T3 (cg-RX-API-DMAC7.html)
PT (1) PT1252184E (cg-RX-API-DMAC7.html)
WO (1) WO2001057079A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10690670B2 (en) 2013-01-20 2020-06-23 Dyax Corp. Assays for determining levels of plasma protease C1 inhibitor
US11754570B2 (en) 2019-04-16 2023-09-12 Takeda Pharmaceutical Company Limited Methods for quantitation of functional C1 esterase inhibitor (FC1-INH)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
DE10112617A1 (de) * 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
AU2003301332B2 (en) * 2002-10-17 2008-06-12 Pharming Intellectual Property B.V. Protein modification
EP1947116B1 (en) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
US7544853B2 (en) * 2003-05-16 2009-06-09 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment
US8071532B2 (en) 2005-12-21 2011-12-06 Pharming Intellectual Property B.V. Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
FR2901796A1 (fr) * 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
JP5507555B2 (ja) * 2008-06-30 2014-05-28 チョ−エー・ファーム・カンパニー・リミテッド 豚のαS1カゼイン遺伝子、そのプロモーター、及びその用途
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
WO2011034421A1 (en) 2009-09-16 2011-03-24 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
EP2305717A1 (en) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
EP2354245A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of hepatic PPAR- activity
EP2354244A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of liver-specific insulin resistance
WO2012026820A2 (en) 2010-08-27 2012-03-01 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
EP2866826B1 (en) 2012-06-27 2025-08-06 Meiragtx UK II Limited Combination for treating an inflammatory disorder
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
ME02865B (me) 2013-03-15 2018-04-20 Shire Viropharma Inc C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae)
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP4212175A1 (en) 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
CN108463243B (zh) * 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
IL326479A (en) 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
BR112020017626A2 (pt) 2018-02-28 2020-12-22 Pharming Intellectual Property B.V. Tratamento e prevenção de pré-eclâmpsia
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー.ブイ. C1エステラーゼ阻害剤によるウイルス感染関連症状の治療
MA71249A (fr) 2022-06-24 2025-04-30 Bioverativ Usa Inc. Méthodes de traitement de maladies médiées par complément

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
WO1991006650A1 (en) * 1989-10-27 1991-05-16 Cetus Corporation C1 inhibitor muteins and uses thereof
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4227762A1 (de) * 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
US6713662B1 (en) * 1994-07-27 2004-03-30 Pharming Intellectual Property B.V. Production of collagen in the milk of transgenic mammals
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10690670B2 (en) 2013-01-20 2020-06-23 Dyax Corp. Assays for determining levels of plasma protease C1 inhibitor
US11892450B2 (en) 2013-01-20 2024-02-06 Takeda Pharmaceutical Company Limited Evaluation, assays and treatment of pKal-mediated disorders
US11754570B2 (en) 2019-04-16 2023-09-12 Takeda Pharmaceutical Company Limited Methods for quantitation of functional C1 esterase inhibitor (FC1-INH)

Similar Documents

Publication Publication Date Title
CA2398707A1 (en) C1 inhibitor produced in the milk of transgenic mammals
JP2012050465A5 (cg-RX-API-DMAC7.html)
Kimelberg et al. The effect of entrapment in liposomes on the in vivo distribution of [3H] methotrexate in a primate
Ruddy et al. C3b inactivator of man: II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b
Katz Iron and protein kinetics studied by means of doubly labeled human crystalline transferrin
CA1329760C (en) Plasma and recombinant protein formulations in high ionic strength media
JPH11509721A (ja) 高純度フォンビルブラント因子の入手方法
JPH0742235B2 (ja) 自己免疫性疾病の予防・治療剤
WO1998023289A1 (en) MODULATION OF IgG BINDING TO FcRn
CZ497290A3 (cs) Isoformy erythropoietinu
JPS6230A (ja) 悪性腫瘍性貧血治療剤
EA014025B1 (ru) Композиции антитела против cd3
Linder et al. Copper transport in mammals
ES2315255T3 (es) Utilizacion de trombopoyetina como medicamento para la terapia y la prevencion de trombocitopenia.
Barandun et al. Clinical tolerance and catabolism of plasmin-treatedγ-globulin for intravenous application
Pearson et al. Studies of ferritin and a new iron-binding protein found in the intestinal mucosa of the rat
Smith et al. Evidence of stem-cell competition in children with malignant disease: a controlled study of hypertransfusion
Kesteven et al. Inhibitor to factor VIII in mild haemophilia
Salter et al. Neonatal role of milk folate-binding protein: studies on the course of digestion of goat's milk folate binder in the 6-d-old kid
JP3634359B2 (ja) Tcf−▲ii▼を有効成分とする血液凝固正常化剤
Baltz et al. In vivo turnover studies of C-reactive protein
Hoffbrand et al. Effect of chronic nutritional iron deficiency on the small intestinal disaccharidase activities of growing dogs
Dahl et al. Bone marrow transplantation without myeloablative conditioning in a mouse model for Diamond-Blackfan anemia corrects the disease phenotype
Moskowitzova et al. Transamniotic Delivery of Coagulation Factor VIII mRNA: A Step Toward a Potential Novel Strategy for the Perinatal Management of Hemophilia A
AU725441B2 (en) An agent for preventing and/or treating multiple organ failure